Literature DB >> 19002119

Pathology of benign prostatic hyperplasia.

C G Roehrborn1.   

Abstract

The epidemiology of benign prostatic hyperplasia (BPH) is complex and not fully understood. The androgenic hormones testosterones and dihydrotestosterone play at least a permissive and important role. Growth factors and other hormones including estrogens may also play a role. BPH is a truely hyperplastic process resulting in growth of glandular-epithelial and stromal/muscle tissue in the prostate, leading to often measurable growth taking on different shapes and configurations which may impact symptoms and secondary outcomes. It is important to recognize that BPH is a histological conditions, which is one but not the only cause of lower urinary tract symptoms, and may or may not be associated with prostate enlargement and bladder outlet obstruction. Recognizing the different entities and determining their presence in individual patients may help with therapeutic decision making.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19002119     DOI: 10.1038/ijir.2008.55

Source DB:  PubMed          Journal:  Int J Impot Res        ISSN: 0955-9930            Impact factor:   2.896


  82 in total

Review 1.  Prostate Artery Embolization.

Authors:  Samdeep Mouli; Elias Hohlastos; Riad Salem
Journal:  Semin Intervent Radiol       Date:  2019-05-22       Impact factor: 1.513

Review 2.  The effect of diet on BPH, LUTS and ED.

Authors:  Mahmoud ElJalby; Dominique Thomas; Dean Elterman; Bilal Chughtai
Journal:  World J Urol       Date:  2018-11-23       Impact factor: 4.226

3.  Diagnosis of transition zone prostate cancer using T2-weighted (T2W) MRI: comparison of subjective features and quantitative shape analysis.

Authors:  Satheesh Krishna; Nicola Schieda; Matthew Df McInnes; Trevor A Flood; Rebecca E Thornhill
Journal:  Eur Radiol       Date:  2018-08-13       Impact factor: 5.315

4.  Expansion of prostate epithelial progenitor cells after inflammation of the mouse prostate.

Authors:  Liang Wang; Marloes Zoetemelk; Brahmananda R Chitteti; Timothy L Ratliff; Jason D Myers; Edward F Srour; Hal Broxmeyer; Travis J Jerde
Journal:  Am J Physiol Renal Physiol       Date:  2015-04-29

Review 5.  Targeting phenotypic heterogeneity in benign prostatic hyperplasia.

Authors:  Douglas W Strand; Daniel N Costa; Franto Francis; William A Ricke; Claus G Roehrborn
Journal:  Differentiation       Date:  2017-08-04       Impact factor: 3.880

6.  Correlation between 5-α reductase type 2 protein expression and methylation of 5-α reductase type 2 promotor gene of benign prostatic hyperplasia.

Authors:  Pil Moon Kang; Young Jin Kim; Won Tae Seo; Su Hwan Kang; Taek Sang Kim; Bong Kwon Chun; Won Ik Seo; Jee-Yeong Jeong; Jae Il Chung
Journal:  World J Urol       Date:  2018-08-01       Impact factor: 4.226

7.  Estrogen receptor beta agonist LY500307 fails to improve symptoms in men with enlarged prostate secondary to benign prostatic hypertrophy.

Authors:  C G Roehrborn; M E Spann; S L Myers; C R Serviss; L Hu; Y Jin
Journal:  Prostate Cancer Prostatic Dis       Date:  2014-11-04       Impact factor: 5.554

8.  Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia.

Authors:  Jae Hung Jung; Balaji Reddy; Karen Ann McCutcheon; Michael Borofsky; Vikram Narayan; Myung Ha Kim; Philipp Dahm
Journal:  Cochrane Database Syst Rev       Date:  2019-05-25

9.  Meta-analysis of vitamin D receptor gene polymorphisms and benign prostatic hyperplasia risk.

Authors:  Xian-Tao Zeng; Qi-Sheng Yao; Hong Weng; Sheng Li; Jing-Yu Huang; Xing-Huan Wang
Journal:  Mol Biol Rep       Date:  2014-07-03       Impact factor: 2.316

Review 10.  Oxytocin in the Male Reproductive Tract; The Therapeutic Potential of Oxytocin-Agonists and-Antagonists.

Authors:  Beatrix Stadler; Michael R Whittaker; Betty Exintaris; Ralf Middendorff
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-22       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.